Alkylphosphocholines as Promising Antitumor Agents: Exploring the Role of Structural Features on the Hemolytic Potential

Laser-Induced Breakdown Spectroscopy and Principal Component Analysis for the Classification of Spectra from Gold-Bearing Ores

Laser-induced breakdown spectroscopy (LIBS) and principal component analysis (PCA) were applied to the classification of LIBS spectra from gold ores prepared as pressed pellets from pulverized bulk samples. For each sample, 5000 single-shot LIBS spectra were obtained. Although the gold concentrations in the samples were as high as 7.7 µg/g, Au emission lines were not observed in most single-shot LIBS spectra, rendering the application of the usual ensemble-averaging approach for spectral processing to be infeasible. Instead, a PCA approach was utilized to analyze the collection of single-shot LIBS spectra. Two spectral ranges of 21 nm and 0.15 nm wide were considered, and LIBS variables (i.e., wavelengths) reduced to no more than three principal components. Single-shot spectra containing Au emission lines (positive spectra) were discriminated by PCA from those without the spectral feature (negative spectra) in a spectral range of less than 1 nm wide around the Au(I) 267.59 nm emission line. Assuming a discrete gold distribution at very low concentration, LIBS sampling of gold particles seemed unlikely; therefore, positive spectra were considered as data outliers. Detection of data outliers was possible using two PCA statistical parameters, i.e., sample residual and Mahalanobis distance. Results from such a classification were compared with a standard database created with positive spectra identified with a filtering algorithm that rejected spectra with an Au intensity below the smallest detectable analytical LIBS signal (i.e., below the LIBS limit of detection). The PCA approach successfully identified 100% of the data outliers when compared with the standard database. False identifications in the multivariate approach were attributed to variations in shot-to-shot intensity and the presence of interfering emission lines.

Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study

Miltefosine (MFS) is an alkylphosphocholine used for the local treatment of cutaneous metastases of breast cancer and oral therapy of visceral leishmaniasis. Recently, the drug was reported in in vitro and preclinical studies to exert significant activity against different developmental stages of schistosomiasis mansoni, a widespread chronic neglected tropical disease (NTD). This justified MFS repurposing as a potential antischistosomal drug. However, five consecutive daily 20 mg/kg doses were needed for the treatment of schistosomiasis mansoni in mice. The present study aims at enhancing MFS efficacy to allow for a single 20mg/kg oral dose therapy using a nanotechnological approach based on lipid nanocapsules (LNCs) as oral nanovectors. MFS was incorporated in LNCs both as membrane-active structural alkylphospholipid component and active antischistosomal agent. MFS-LNC formulations showed high entrapment efficiency (EE%), good colloidal properties, sustained release pattern and physical stability. Further, LNCs generally decreased MFS-induced erythrocyte hemolytic activity used as surrogate indicator of membrane activity. While MFS-free LNCs exerted no antischistosomal effect, statistically significant enhancement was observed with all MFS-LNC formulations. A maximum effect was achieved with MFS-LNCs incorporating CTAB as positive charge imparting agent or oleic acid as membrane permeabilizer. Reduction of worm load, ameliorated liver pathology and extensive damage of the worm tegument provided evidence for formulation-related efficacy enhancement. Non-compartmental analysis of pharmacokinetic data obtained in rats indicated independence of antischistosomal activity on systemic drug exposure, suggesting possible gut uptake of the stable LNCs and targeting of the fluke tegument which was verified by SEM. The study findings put forward MFS-LNCs as unique oral nanovectors combining the bioactivity of MFS and biopharmaceutical advantages of LNCs, allowing targeting via the oral route. From a clinical point of view, data suggest MFS-LNCs as a potential single dose oral nanomedicine for enhanced therapy of schistosomiasis mansoni and possibly other diseases.